Brad Fluegel
Angel Investor
Chicago, United States
Brad Fluegel is a Series A investor in Chicago focused on PaaS and SaaS. Brad Fluegel is senior vice president, chief strategy and business development officer for Walgreen Co., based in Deerfield, Illinois. Fluegel is responsible for corporate strategy and business development, as well as developing and implementing Healthcare Clinic, clinical office and healthcare innovation strategies.Fluegel joined Walgreens inOctober 2012 after previously serving as executive in residence at Health Evolution Partners. Before that he was executive vice president and chief strategy and external affairs officer of Wellpoint, among the nation’s largest health benefits companies. While at Wellpoint, Fluegel was responsible for long-term strategic planning, government affairs, corporate communications including public relations, corporate marketing, corporate development, international expansion, innovation and new business ventures.Prior to Wellpoint, Fluegel was senior vice president of national accounts and vice president, enterprise strategy at Aetna, Inc. In this role, he led the national accounts business and was responsible for developing and executing on strategies that expanded Aetna’s position as a leader in the large employer market. As head of enterprise strategy, Fluegel worked closely with Aetna’s executive committee and board of directors to advance the company’s medium- and long-term business strategies, and ran an internal consulting group responsible for driving management process and operating efficiency across the enterprise.Earlier, Fluegel was CEO for Reden & Anders (Ingenix Consulting) and Tillinghast-Towers Perrin, a clinical, actuarial and management consulting practice that served all sectors of the health care industry. While there, he negotiated the sale of Tillinghast Health to Ingenix. Fluegel also held several roles in strategy, planning and product development and management at Harvard Community Health Plan and organized and led audits, feasibility studies and related projects for health care clients at Arthur Andersen & Co.In addition to his duties at Walgreens, Fluegel currently serves on the board of directors of Metropolitan Jewish Health System (New York, NY), Health Integrated, Inc. (Tampa, FL) and Performant Financial Corporation (Livermore, CA).Fluegel earned a master’s degree in public policy from Harvard University’s Kennedy School of Government and a bachelor of arts in business administration from the University of Washington. He also serves as a lecturer at the University of Pennsylvania’s Wharton School of Business.
- Total investments:
- 1
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Brad Fluegel invests in
Stages Brad Fluegel invests in
Countries Brad Fluegel invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- PaaS 1 (100%)
- SaaS 1 (100%)
- Software 1 (100%)
- Health Care 1 (100%)
- Personal Health 1 (100%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Idoven has developed the world’s first AI cardiologist -Willem- that augments both a cardiologist’s and non-cardiology expert clinician’s ability to identify, triage and diagnose patients at scale through APIs. The company counts clients such as AstraZeneca, Abbott, Novartis, GE Healthcare, FIFPRO, Google, Santander and Real Madrid Foundation.Idoven is backed by top-tier investors and business angels including Insight Partners, Northzone and Wayra (Telefónica), Iker Casillas, Pau Gasol, the Accel Starters program, EIC Accelerator, Horizon 2020, ERC and EIT Health. The company has been awarded with numerous distinctions for its AI technology in Europe and the US, including the the European Seal of Excellence 3x from the European Commission, granted by Horizon 2020, European Research Council ERC 2x (RIA) Europe’s most prestigious research grant, supporting excellent researchers in carrying out ground-breaking, high-risk, high-gain, frontier research projects, EIC Accelerator, and EIT Health. Idoven was ranked #1 Spanish HealthTech company in 2020 by NEOTEC. Idoven has been Google for Startups Resident at Google Campus Madrid and part of the Google for Startups Global Alumni Program. The company has won the prize Emprendedor XXI from CaixaBank, the Healthy Longevity Catalyst Award from the U.S. National Academy of Medicine, and has been awarded at South Summit 2021 as the Most Disruptive Startup, and Best Health and Wellbeing Startup. Selected by CB Insights as one of the top 150 global companies in Digital Health for 2022, and top 50 global companies in Digital Health for 2023. Idoven was recognized by TIME Magazine as one of the World's Top HealthTech Companies of 2025. | $19.5M / Series A / Jun 21, 2022 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Brad Fluegel invest in?
Brad Fluegel invests primarily in PaaS, SaaS and Software startups, most often at Series A stage. Most of the 1 investments tracked by Shizune back companies in Spain. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Brad Fluegel?
Public channels for Brad Fluegel include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Brad Fluegel last invest?
The most recent investment recorded for Brad Fluegel closed in Jun 2022. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
